AbbVieABBV
Market Cap: 327B
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
29% more call options, than puts
Call options by funds: $3.29B | Put options by funds: $2.55B
16% more capital invested
Capital invested by funds: $192B [Q4 2023] → $223B (+$31.3B) [Q1 2024]
11% more first-time investments, than exits
New positions opened: 206 | Existing positions closed: 186
11% more funds holding in top 10
Funds holding in top 10: 197 [Q4 2023] → 218 (+21) [Q1 2024]
1% more funds holding
Funds holding: 3,226 [Q4 2023] → 3,246 (+20) [Q1 2024]
0.6% less ownership
Funds ownership: 70.21% [Q4 2023] → 69.61% (-0.6%) [Q1 2024]
11% less repeat investments, than reductions
Existing positions increased: 1,284 | Existing positions reduced: 1,443
Research analyst outlook
21 Wall Street Analysts provided 1 year price forecasts over the past 6 months
21 analyst ratings
Cantor Fitzgerald Louise Chen | 8%upside $200 | Overweight Reiterated | 26 Jul 2024 |
Truist Securities Robyn Karnauskas | 13%upside $210 | Buy Reiterated | 26 Jul 2024 |
Wells Fargo Mohit Bansal | 11%upside $205 | Overweight Maintained | 26 Jul 2024 |
Barclays Carter Gould | 8%upside $200 | Overweight Maintained | 26 Jul 2024 |
BMO Capital Evan David Seigerman | 16%upside $214 | Outperform Maintained | 19 Jul 2024 |
Financial journalist opinion
Based on 67 articles about ABBV published over the past 30 days